Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 1;29(9):1382-1401.e8.
doi: 10.1016/j.stem.2022.08.007.

Modeling human multi-lineage heart field development with pluripotent stem cells

Affiliations
Free article

Modeling human multi-lineage heart field development with pluripotent stem cells

Donghe Yang et al. Cell Stem Cell. .
Free article

Abstract

The cardiomyocyte (CM) subtypes in the mammalian heart derive from distinct lineages known as the first heart field (FHF), the anterior second heart field (aSHF), and the posterior second heart field (pSHF) lineages that are specified during gastrulation. We modeled human heart field development from human pluripotent stem cells (hPSCs) by using single-cell RNA-sequencing to delineate lineage specification and progression. Analyses of hPSC-derived and mouse mesoderm transcriptomes enabled the identification of distinct human FHF, aSHF, and pSHF mesoderm subpopulations. Through staged manipulation of signaling pathways identified from transcriptomics, we generated myocyte populations that display molecular characteristics of key CM subtypes. The developmental trajectory of the human cardiac lineages recapitulated that of the mouse, demonstrating conserved cardiovascular programs. These findings establish a comprehensive landscape of human embryonic cardiogenesis that provides access to a broad spectrum of cardiomyocytes for modeling congenital heart diseases and chamber-specific cardiomyopathies as well as for developing new therapies to treat them.

Keywords: cardiac mesoderm specification; cardiomyocyte subtypes; hPSC models; human and mouse comparison; human heart field development; scRNA-seq.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests G.M.K. is a scientific founder and paid consultant for BlueRock Therapeutics, LP, a paid consultant for VistaGen Therapeutics, and a board member of Anagenesis Biotechnologies. M.A.L. is a paid consultant for BlueRock Therapeutics, LP. G.M.K. and D.Y. declare a patent titled “Cardiomyocyte subtypes and methods of making and using” (no. PCT/IB2022/055,425) related to this work.

Comment in

Publication types

Grants and funding

LinkOut - more resources